NASDAQ:TLRY - Tilray Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$67.16 -3.09 (-4.40 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$67.16
Today's Range$66.50 - $69.88
52-Week Range$20.10 - $300.00
Volume1.61 million shs
Average Volume2.79 million shs
Market Capitalization$6.26 billion
P/E Ratio-81.90
Dividend YieldN/A
BetaN/A
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone206-432-9325

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.13 million

Profitability

Net Income$-7,800,000.00
Net Margins-157.05%

Miscellaneous

EmployeesN/A
Market Cap$6.26 billion
Next Earnings Date6/17/2019 (Estimated)
OptionableOptionable

Tilray (NASDAQ:TLRY) Frequently Asked Questions

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) posted its earnings results on Monday, March, 18th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.19. The firm earned $15.50 million during the quarter, compared to the consensus estimate of $12.85 million. Tilray had a negative net margin of 157.05% and a negative return on equity of 76.39%. The company's revenue was up 203.9% compared to the same quarter last year. View Tilray's Earnings History.

When is Tilray's next earnings date?

Tilray is scheduled to release their next quarterly earnings announcement on Monday, June 17th 2019. View Earnings Estimates for Tilray.

What price target have analysts set for TLRY?

7 brokers have issued 1-year target prices for Tilray's shares. Their forecasts range from $35.00 to $200.00. On average, they anticipate Tilray's stock price to reach $106.5167 in the next twelve months. This suggests a possible upside of 58.6% from the stock's current price. View Analyst Price Targets for Tilray.

What is the consensus analysts' recommendation for Tilray?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tilray.

What are Wall Street analysts saying about Tilray stock?

Here are some recent quotes from research analysts about Tilray stock:
  • 1. Jefferies Financial Group Inc analysts commented, "We initiate at Underperform, PT $61. With arguably inferior positioning in parts of its business vs. certain peers (questionable Canada rec approach, less impressive US optionality, too much value credited to ABI/ABG), we struggle to justify the current valuation. We appreciate it is well placed in medical but future value here will be driven by IP for which little visibility near term. Its share structure also raises risk of increased volatility." (3/8/2019)
  • 2. According to Zacks Investment Research, "Tilray, Inc. is a pharmaceutical company. It develops cannabis based medicines, drugs, drops and oil products. Tilray, Inc. is based in NANAIMO, Canada. " (1/15/2019)

Has Tilray been receiving favorable news coverage?

Media stories about TLRY stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tilray earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH) and Square (SQ).

Who are Tilray's key executives?

Tilray's management team includes the folowing people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ETF Managers Group LLC (0.58%), Park West Asset Management LLC (0.03%), D. E. Shaw & Co. Inc. (0.03%), Raging Capital Management LLC (0.03%), Creative Planning (0.02%) and Two Sigma Investments LP (0.01%). Company insiders that own Tilray stock include Brendan Kennedy, Edward Wood Pastorius Jr and Mark Castaneda. View Institutional Ownership Trends for Tilray.

Which major investors are selling Tilray stock?

TLRY stock was sold by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc. and Belpointe Asset Management LLC. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Edward Wood Pastorius Jr and Mark Castaneda. View Insider Buying and Selling for Tilray.

Which major investors are buying Tilray stock?

TLRY stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Park West Asset Management LLC, D. E. Shaw & Co. Inc., Raging Capital Management LLC, Two Sigma Investments LP, Virtu Financial LLC, Exane Derivatives and Creative Planning. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy and Edward Wood Pastorius Jr. View Insider Buying and Selling for Tilray.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $67.16.

How big of a company is Tilray?

Tilray has a market capitalization of $6.26 billion and generates $43.13 million in revenue each year. The company earns $-7,800,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

What is Tilray's official website?

The official website for Tilray is http://www.tilray.com.

How can I contact Tilray?

Tilray's mailing address is 1920 EASTLAKE AVENUE E., SEATTLE WA, 98102. The company can be reached via phone at 206-432-9325.


MarketBeat Community Rating for Tilray (NASDAQ TLRY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  519
MarketBeat's community ratings are surveys of what our community members think about Tilray and other stocks. Vote "Outperform" if you believe TLRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel